Search

Your search keyword '"Peng, Shoujiao"' showing total 11 results
Start Over Author "Peng, Shoujiao" Search Limiters Full Text
11 results on '"Peng, Shoujiao"'

2. Bufotalin Induces Oxidative Stress-Mediated Apoptosis by Blocking the ITGB4/FAK/ERK Pathway in Glioblastoma.

Author

Tan, Junchao, Lin, Guoqiang, Zhang, Rui, Wen, Yuting, Luo, Chunying, Wang, Ran, Wang, Feiyun, Peng, Shoujiao, and Zhang, Jiange

Subjects
TUMOR growth, REACTIVE oxygen species, PROTEIN analysis, GLIOBLASTOMA multiforme, CELL survival
Abstract

Bufotalin (BT), a major active constituent of Chansu, has been found to possess multiple pharmacological activities. Although previous studies have shown that BT could inhibit the growth of glioblastoma (GBM), the safety of BT in vivo and the potential mechanism are still unclear. We conducted a systematic assessment to investigate the impact of BT on GBM cell viability, migration, invasion, and colony formation. Furthermore, in vivo results were obtained to evaluate the effect of BT on tumor growth. The preliminary findings of our study demonstrate the effective inhibition of GBM cell growth and subcutaneous tumor development in mice by BT, with tolerable levels of tolerance observed. Mechanistically, BT treatment induced mitochondrial dysfunction, bursts of reactive oxygen species (ROS), and subsequent cell apoptosis. More importantly, proteomic-based differentially expressed proteins analysis revealed a significant downregulation of integrin β4 (ITGB4) following BT treatment. Furthermore, our evidence suggested that the ITGB4/focal adhesion kinase (FAK)/extracellular signal-related kinase (ERK) pathway involved BT-induced apoptosis. Overall, our study demonstrates the anti-GBM effects of BT and elucidates the underlying mechanism, highlighting BT as a potential therapeutic option for GBM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Tumor-derived OBP2A promotes prostate cancer castration resistance

Author

Jeong, Ji-Hak, primary, Zhong, Shangwei, additional, Li, Fuzhuo, additional, Huang, Changhao, additional, Chen, Xueyan, additional, Liu, Qingqing, additional, Peng, Shoujiao, additional, Park, HaJeung, additional, Lee, You Mie, additional, Dhillon, Jasreman, additional, and Luo, Jun-Li, additional

Published
2022
Full Text
View/download PDF

6. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

Author

Guo, Yan, primary, He, Wenhui, additional, Mou, Huihui, additional, Zhang, Lizhou, additional, Chang, Jing, additional, Peng, Shoujiao, additional, Ojha, Amrita, additional, Tavora, Rubens, additional, Parcells, Mark S., additional, Luo, Guangxiang, additional, Li, Wenhui, additional, Zhong, Guocai, additional, Choe, Hyeryun, additional, Farzan, Michael, additional, and Quinlan, Brian D., additional

Published
2021
Full Text
View/download PDF

7. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2

Author

Mou, Huihui, primary, Quinlan, Brian D., additional, Peng, Haiyong, additional, Liu, Guanqun, additional, Guo, Yan, additional, Peng, Shoujiao, additional, Zhang, Lizhou, additional, Davis-Gardner, Meredith E., additional, Gardner, Matthew R., additional, Crynen, Gogce, additional, DeVaux, Lindsey B., additional, Voo, Zhi Xiang, additional, Bailey, Charles C., additional, Alpert, Michael D., additional, Rader, Christoph, additional, Gack, Michaela U., additional, Choe, Hyeryun, additional, and Farzan, Michael, additional

Published
2021
Full Text
View/download PDF

10. Tumor-derived OBP2A promotes prostate cancer castration resistance

Author

Jeong, Ji-Hak, Zhong, Shangwei, Li, Fuzhuo, Huang, Changhao, Chen, Xueyan, Liu, Qingqing, Peng, Shoujiao, Park, HaJeung, Lee, You Mie, Dhillon, Jasreman, and Luo, Jun-Li

Abstract

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors in remission is almost completely ignored. Here, we report that odorant-binding protein (OBP2A) released from tumors in remission during ADT catches survival factors, such as CXCL15/IL8, to promote PCa cell androgen-independent growth and enhance the infiltration of myeloid-derived suppressor cells (MDSCs) into tumor microenvironment, leading to the emergence of castration resistance. OBP2A knockdown significantly inhibits CRPC and metastatic CRPC development and improves therapeutic efficacy of CTLA-4/PD-1 antibodies. Treatment with OBP2A-binding ligand α-pinene interrupts the function of OBP2A and suppresses CRPC development. Furthermore, α-pinene–conjugated doxorubicin/docetaxel can be specifically delivered to tumors, resulting in improved anticancer efficacy. Thus, our studies establish a novel concept for the emergence of PCa castration resistance and provide new therapeutic strategies for advanced PCa.

Published
2023
Full Text
View/download PDF

11. An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines.

Author

Quinlan BD, He W, Mou H, Zhang L, Guo Y, Chang J, Peng S, Ojha A, Tavora R, Parcells MS, Luo G, Li W, Zhong G, Choe H, and Farzan M

Abstract

The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates viral entry into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. The RBD is the primary SARS-CoV-2 neutralizing epitope and a critical target of any SARS-CoV-2 vaccine. Here we show that this RBD conjugated to each of two carrier proteins elicited more potent neutralizing responses in immunized rodents than did a similarly conjugated proline-stabilized S-protein ectodomain. Nonetheless, the native RBD expresses inefficiently, limiting its usefulness as a vaccine antigen. However, we show that an RBD engineered with four novel glycosylation sites (gRBD) expresses markedly more efficiently, and generates a more potent neutralizing responses as a DNA vaccine antigen, than the wild-type RBD or the full-length S protein, especially when fused to multivalent carriers such as an H. pylori ferritin 24-mer. Further, gRBD is more immunogenic than the wild-type RBD when administered as a subunit protein vaccine. Our data suggest that multivalent gRBD antigens can reduce costs and doses, and improve the immunogenicity, of all major classes of SARS-CoV-2 vaccines., Competing Interests: Competing interests: A patent for gRBD has been filed by The Scripps Research Institute in which B.D.Q, W.L., H.M., and M.F. are listed as inventors.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results